Trump anuncia ataques contra Irán por burlarse de EE.UU. con el acuerdo de paz Ivar AI

BBC News

EUA lançam novos ataques contra o Irã após Trump ameaçar 'atingir o país com força' diante da falta de acordo

Aristeguinoticias.com

Trump anuncia ataques contra Irán por burlarse de EE.UU. con el acuerdo de paz

Crypto Briefing

Houthis impose total naval blockade on Israel in Red Sea escalation

PBS

Exchange of missile strikes between Israel and Iran threatens fragile ceasefire

Crypto Briefing

Cynthia Lummis calls for US to accumulate Bitcoin openly while other nations buy quietly

New York Post

ChatGPT maker OpenAI files for IPO looking to capitalize on investor appetite for AI boom

Macdailynews.com

Apple’s iPhone momentum shines bright: 19.7% YoY production surge positions it for market leadership amid industry headwinds

Www.abc.es

EE.UU. ataca Irán «en legítima defensa» por el «derribo» de un helicóptero en Ormuz

PRNewswire

Oracle Announces Record Q4 and FY 2026 Results Driven by Cloud Infrastructure & Cloud Applications

Crypto Briefing

American Bitcoin grows BTC balance sheet to 7,021 coins, cites 50% mining margin

CNA

Nvidia announces deals with South Korea's SK Hynix, Naver and Doosan for AI data centres

Crypto Briefing

Trump says Iran deal ‘very close,’ could impact troop withdrawal

Xataka.com.mx

Dreame ya se convirtió en la pesadilla de Xiaomi donde su calidad-precio era insuperable: las aspiradoras robots

Yahoo Entertainment

《大賣空》本尊示警！AI三巨頭IPO募資規模超越網路泡沫

GlobeNewswire

Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL

TechRadar

This Microsoft Defender zero-day could give hackers unprecedented access to your system

$Cellectis reçoit le statut RMAT de la FDA pour lasmé-cel, la première thérapie CAR-T allogénique en essai pivot pour les patients atteints de LLA-B en rechute ou réfractaire$

GlobeNewswire

Cellectis reçoit le statut RMAT de la FDA pour lasmé-cel, la première thérapie CAR-T allogénique en essai pivot pour les patients atteints de LLA-B en rechute ou réfractaire